Atossa Therapeutics (ATOS)

Company Profile

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19.

Company profile

Ticker

ATOS

Exchange

NASDAQ

Website

atossatherapeutics.com

CEO

Steven Quay

Incorporated

Delaware

Location

Washington

Fiscal year end

Dec 31

Sector

Manufacturing > Surgical and Medical Instrument Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Abbott Laboratories • Teva- Pharmaceutical Industries • Bristol-Myers Squibb • Lilly(Eli) & Co • Viatris • Abbvie • Celgene ...

Former names

ATOSSA GENETICS INC

SEC CIK

0001488039

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

IRS number

264753208

ATOS stock data

1M 1Y 5Y

Latest filings (excl ownership)

View all

7 Nov 22

Atossa Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate Update

7 Nov 22

8-K

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard

8 Aug 22

Atossa Therapeutics Announces Second Quarter 2022 Financial Results and Provides Corporate Update

Regulation FD Disclosure

1 Jul 22

8-K

Regulation FD Disclosure

6 Jun 22

8-K

Submission of Matters to a Vote of Security Holders

9 May 22

Transcripts

ATOS

Earnings call transcript

2022 Q2

27 Jul 22

Latest ownership filings

View all

CVI Investments, Inc.

Financial summary

Financial statements Chart ATOS financial data

Quarter (USD)	Sep 22	Jun 22	Mar 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 21	Dec 20	Dec 19	Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	117.48 mm	117.48 mm	117.48 mm	117.48 mm	117.48 mm	117.48 mm
Cash burn (monthly)	2.72 mm	1.89 mm	2.74 mm	2.04 mm	1.80 mm	1.66 mm
Cash used (since last report)	10.79 mm	7.48 mm	10.83 mm	8.08 mm	7.14 mm	6.57 mm
Cash remaining	106.69 mm	109.99 mm	106.64 mm	109.39 mm	110.33 mm	110.91 mm
Runway (months of cash)	39.2	58.2	39.0	53.6	61.2	66.9

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2022

ATOS institutional ownership history Ownership history

22.5% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	54	73	-26.0%
Opened positions	6	15	-60.0%
Closed positions	25	26	-3.8%
Increased positions	7	7	–
Reduced positions	22	33	-33.3%

13F shares	Current	Prev Q	Change
Total value	17.35 mm	47.28 mm	-63.3%
Total shares	28.52 mm	33.28 mm	-14.3%
Total puts	662.80 k	335.70 k	+97.4%
Total calls	1.59 mm	578.90 k	+173.9%
Total put/call ratio	0.4	0.6	-27.9%

Largest owners	Shares	Value	Change
CVI Investments	7.76 mm	$0.00	0.0%
Vanguard	5.69 mm	$4.75 mm	-10.9%
BLK Blackrock	3.53 mm	$2.95 mm	-1.5%
Intracoastal Capital	2.25 mm	$1.94 mm	0.0%
Laurion Capital Management	2.23 mm	$1.86 mm	0.0%
D. E. Shaw & Co.	1.77 mm	$1.47 mm	-22.5%
Geode Capital Management	1.22 mm	$1.02 mm	+0.2%
Renaissance Technologies	1.10 mm	$913.00 k	-44.9%
Millennium Management	669.76 k	$558.00 k	-56.4%
Sabby Management	411.90 k	$343.00 k	-21.5%

Largest transactions	Shares	Bought/sold	Change
Renaissance Technologies	1.10 mm	-894.29 k	-44.9%
Millennium Management	669.76 k	-864.74 k	-56.4%
Vanguard	5.69 mm	-698.52 k	-10.9%
D. E. Shaw & Co.	1.77 mm	-512.30 k	-22.5%
STT State Street	0.00	-481.00 k	EXIT
BMO Bank of Montreal	0.00	-309.60 k	EXIT
Citadel Advisors	25.92 k	-217.85 k	-89.4%
Ergoteles	316.25 k	-198.35 k	-38.5%
Sabby Management	411.90 k	-112.91 k	-21.5%
Mariner	104.86 k	+104.86 k	NEW

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

ATOS insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
13 May 22	Gregory L Weaver	Stock Option Common Stock	Grant	Acquire A	No	No	0.93	50,000	46.50 k	50,000
13 May 22	Stephen J Galli	Stock Option Common Stock	Grant	Acquire A	No	No	0.93	50,000	46.50 k	50,000
13 May 22	Remmel H. Lawrence	Stock Option Common Stock	Grant	Acquire A	No	No	0.93	50,000	46.50 k	50,000
13 May 22	Chen Shu-Chih	Stock Option Common Stock	Grant	Acquire A	No	No	0.93	50,000	46.50 k	50,000
13 May 22	Richard I Steinhart	Stock Option Common Stock	Grant	Acquire A	No	No	0.93	50,000	46.50 k	500,000